Business Context and Reporting Period
Company: Prothena Corporation Public Limited Company (Ireland)
Filing Type: Form 8-K (Current Report)
Date of Report: September 24, 2018
Event: Entry into a Material Definitive Agreement (Sub-Sublease of office and laboratory space).
Key Financial Metrics and Transaction Terms
This filing details a real estate transaction rather than standard operating financial results. Key metrics include:
- Property Size: Approximately 46,641 square feet of office and laboratory space in South San Francisco, California.
- Initial Annual Base Rent: Approximately $2.7 million.
- Rent Escalation: Increases of approximately 3.5% annually starting September 1, 2019.
- Lease Term: Commenced September 24, 2018; terminates December 15, 2023.
- Additional Costs: Sub-Subtenant (Assembly Biosciences, Inc.) is responsible for allocated operating expenses, real property taxes, a 3.0% management fee on base rent, and certain pass-through charges.
- Revenue Sharing: Prothena must pay 50% of the excess cash received from the Sub-Subtenant (over Prothena's base rent to the Sublandlord) to the Sublandlord (Amgen Inc.), after deducting certain costs.
Material Changes and Operational Details
The filing reports the execution of a Consent to Sub-Sublease effective September 19, 2018, allowing Prothena Biosciences Inc. (PBI) to sub-sublease space previously subleased from Amgen Inc. Key operational details include:
- Delivery Schedule: PBI is required to use good faith efforts to deliver the complete premises by November 30, 2018, with staged delivery permitted.
- Expansion Option: The Sub-Subtenant has an option to expand by approximately 33,137 square feet, exercisable by December 31, 2019, subject to landlord consent.
- Right of First Refusal: The Sub-Subtenant holds a right of first refusal on future sub-subleases of portions of the premises.
- Termination Conditions: The agreement terminates if the Master Lease or Sublease terminates, or upon material casualty, condemnation, or default.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding future earnings. However, it outlines specific contractual risks and contingencies:
- Dependency Risk: The Sub-Sublease is contingent upon the continued existence of the Master Lease and Sublease with Amgen Inc. and HCP BTC, LLC.
- Consent Requirements: Expansion options and rights of first refusal are subject to the consent of the Master Landlord and Sublandlord.
- Default Risk: PBI may terminate the agreement if the Sub-Subtenant fails to pay amounts owing.
Important Facts for Investor Verification
- Verify the impact of the 50% revenue-sharing clause with Amgen Inc. on the net economic benefit of this lease to Prothena.
- Confirm the status of the "good faith efforts" to deliver the full premises by the November 30, 2018 deadline.
- Review the full text of the Sub-Sublease and Consent (filed as exhibits to the Q3 2018 Form 10-Q) for complete terms regarding operating expense allocations and termination rights.
- Assess the potential future cash flow impact if the Sub-Subtenant exercises the expansion option for an additional 33,137 square feet.